nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—Myeloid leukaemia—Thiotepa—sarcoma	0.0427	0.0836	CcSEcCtD
Clodronate—Acute myeloid leukaemia—Thiotepa—sarcoma	0.0273	0.0534	CcSEcCtD
Clodronate—SLC25A6—Vinorelbine—Vincristine—sarcoma	0.0208	1	CbGdCrCtD
Clodronate—SLC25A4—mammary gland—sarcoma	0.0196	0.0491	CbGeAlD
Clodronate—Myeloid leukaemia—Epirubicin—sarcoma	0.0172	0.0337	CcSEcCtD
Clodronate—SLC25A6—embryo—sarcoma	0.0164	0.0411	CbGeAlD
Clodronate—Myeloid leukaemia—Doxorubicin—sarcoma	0.0159	0.0311	CcSEcCtD
Clodronate—Acute leukaemia—Thiotepa—sarcoma	0.0157	0.0307	CcSEcCtD
Clodronate—SLC25A5—myometrium—sarcoma	0.0148	0.0372	CbGeAlD
Clodronate—SLC25A6—hematopoietic system—sarcoma	0.0146	0.0367	CbGeAlD
Clodronate—SLC25A5—embryo—sarcoma	0.0143	0.0358	CbGeAlD
Clodronate—SLC25A6—connective tissue—sarcoma	0.0141	0.0354	CbGeAlD
Clodronate—SLC25A5—seminal vesicle—sarcoma	0.0134	0.0336	CbGeAlD
Clodronate—PTGS2—periosteum—sarcoma	0.0133	0.0332	CbGeAlD
Clodronate—SLC25A5—hematopoietic system—sarcoma	0.0127	0.032	CbGeAlD
Clodronate—SLC25A6—skin of body—sarcoma	0.0127	0.0319	CbGeAlD
Clodronate—SLC25A5—connective tissue—sarcoma	0.0123	0.0308	CbGeAlD
Clodronate—Hyperphosphataemia—Mitoxantrone—sarcoma	0.0113	0.0222	CcSEcCtD
Clodronate—Acute leukaemia—Etoposide—sarcoma	0.0113	0.022	CcSEcCtD
Clodronate—SLC25A5—smooth muscle tissue—sarcoma	0.0112	0.0281	CbGeAlD
Clodronate—SLC25A5—skin of body—sarcoma	0.0111	0.0278	CbGeAlD
Clodronate—SLC25A6—uterus—sarcoma	0.0111	0.0277	CbGeAlD
Clodronate—Acute myeloid leukaemia—Epirubicin—sarcoma	0.011	0.0215	CcSEcCtD
Clodronate—PTGS2—leg—sarcoma	0.0106	0.0265	CbGeAlD
Clodronate—SLC25A6—lymphoid tissue—sarcoma	0.0103	0.0259	CbGeAlD
Clodronate—Acute myeloid leukaemia—Doxorubicin—sarcoma	0.0102	0.0199	CcSEcCtD
Clodronate—SLC25A5—cardiac atrium—sarcoma	0.00967	0.0243	CbGeAlD
Clodronate—SLC25A5—uterus—sarcoma	0.00962	0.0241	CbGeAlD
Clodronate—PTGS2—hindlimb—sarcoma	0.00943	0.0237	CbGeAlD
Clodronate—SLC25A6—bone marrow—sarcoma	0.00939	0.0235	CbGeAlD
Clodronate—PTGS2—cartilage tissue—sarcoma	0.00929	0.0233	CbGeAlD
Clodronate—Stomach ache—Mitoxantrone—sarcoma	0.0091	0.0178	CcSEcCtD
Clodronate—SLC25A4—cardiac atrium—sarcoma	0.00907	0.0227	CbGeAlD
Clodronate—SLC25A5—lymphoid tissue—sarcoma	0.00897	0.0225	CbGeAlD
Clodronate—SLC25A5—tendon—sarcoma	0.00843	0.0211	CbGeAlD
Clodronate—SLC25A5—bone marrow—sarcoma	0.00817	0.0205	CbGeAlD
Clodronate—PTGS2—appendage—sarcoma	0.00809	0.0203	CbGeAlD
Clodronate—SLC25A6—testis—sarcoma	0.00803	0.0201	CbGeAlD
Clodronate—SLC25A4—tendon—sarcoma	0.0079	0.0198	CbGeAlD
Clodronate—SLC25A6—liver—sarcoma	0.00759	0.019	CbGeAlD
Clodronate—Local reaction—Mitoxantrone—sarcoma	0.00699	0.0137	CcSEcCtD
Clodronate—SLC25A5—testis—sarcoma	0.00698	0.0175	CbGeAlD
Clodronate—SLC25A5—liver—sarcoma	0.0066	0.0166	CbGeAlD
Clodronate—SLC25A4—testis—sarcoma	0.00654	0.0164	CbGeAlD
Clodronate—Acute leukaemia—Epirubicin—sarcoma	0.00631	0.0124	CcSEcCtD
Clodronate—Serum creatinine increased—Mitoxantrone—sarcoma	0.00629	0.0123	CcSEcCtD
Clodronate—SLC25A4—liver—sarcoma	0.00619	0.0155	CbGeAlD
Clodronate—Acute leukaemia—Doxorubicin—sarcoma	0.00584	0.0114	CcSEcCtD
Clodronate—SLC25A6—lymph node—sarcoma	0.00582	0.0146	CbGeAlD
Clodronate—Hyperphosphataemia—Epirubicin—sarcoma	0.00528	0.0103	CcSEcCtD
Clodronate—Neoplasm malignant—Thiotepa—sarcoma	0.00525	0.0103	CcSEcCtD
Clodronate—Extravasation—Thiotepa—sarcoma	0.00514	0.0101	CcSEcCtD
Clodronate—Extravasation—Dactinomycin—sarcoma	0.0051	0.00997	CcSEcCtD
Clodronate—SLC25A5—lymph node—sarcoma	0.00506	0.0127	CbGeAlD
Clodronate—Hyperphosphataemia—Doxorubicin—sarcoma	0.00489	0.00956	CcSEcCtD
Clodronate—PTGS2—endothelium—sarcoma	0.00489	0.0123	CbGeAlD
Clodronate—Oliguria—Thiotepa—sarcoma	0.00486	0.00951	CcSEcCtD
Clodronate—Hypocalcaemia—Dactinomycin—sarcoma	0.00486	0.00951	CcSEcCtD
Clodronate—SLC25A4—lymph node—sarcoma	0.00474	0.0119	CbGeAlD
Clodronate—SLC25A5—Host Interactions of HIV factors—NPM1—sarcoma	0.00459	0.0661	CbGpPWpGaD
Clodronate—Extravasation—Vincristine—sarcoma	0.00455	0.00891	CcSEcCtD
Clodronate—Extravasation—Mitoxantrone—sarcoma	0.00444	0.00868	CcSEcCtD
Clodronate—Proteinuria—Mitoxantrone—sarcoma	0.0044	0.00862	CcSEcCtD
Clodronate—Protein urine present—Mitoxantrone—sarcoma	0.00434	0.0085	CcSEcCtD
Clodronate—Hypocalcaemia—Mitoxantrone—sarcoma	0.00423	0.00827	CcSEcCtD
Clodronate—SLC25A6—Host Interactions of HIV factors—NPM1—sarcoma	0.00385	0.0554	CbGpPWpGaD
Clodronate—Extravasation—Etoposide—sarcoma	0.00369	0.00722	CcSEcCtD
Clodronate—Cardiac failure—Thiotepa—sarcoma	0.00333	0.00652	CcSEcCtD
Clodronate—Local reaction—Epirubicin—sarcoma	0.00326	0.00638	CcSEcCtD
Clodronate—Blood creatinine increased—Thiotepa—sarcoma	0.00305	0.00596	CcSEcCtD
Clodronate—Renal failure acute—Mitoxantrone—sarcoma	0.00304	0.00595	CcSEcCtD
Clodronate—Dehydration—Thiotepa—sarcoma	0.00303	0.00592	CcSEcCtD
Clodronate—Local reaction—Doxorubicin—sarcoma	0.00302	0.0059	CcSEcCtD
Clodronate—SLC25A4—Host Interactions of HIV factors—NPM1—sarcoma	0.003	0.0432	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—NPM1—sarcoma	0.00298	0.043	CbGpPWpGaD
Clodronate—Serum creatinine increased—Epirubicin—sarcoma	0.00293	0.00574	CcSEcCtD
Clodronate—Cardiac failure—Mitoxantrone—sarcoma	0.00288	0.00563	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Thiotepa—sarcoma	0.00287	0.00561	CcSEcCtD
Clodronate—PTGS2—myometrium—sarcoma	0.00279	0.00701	CbGeAlD
Clodronate—Dysphagia—Dactinomycin—sarcoma	0.00279	0.00546	CcSEcCtD
Clodronate—Serum creatinine increased—Doxorubicin—sarcoma	0.00271	0.00531	CcSEcCtD
Clodronate—PTGS2—embryo—sarcoma	0.00269	0.00674	CbGeAlD
Clodronate—Dehydration—Vincristine—sarcoma	0.00268	0.00525	CcSEcCtD
Clodronate—Blood creatinine increased—Mitoxantrone—sarcoma	0.00263	0.00515	CcSEcCtD
Clodronate—Dehydration—Mitoxantrone—sarcoma	0.00261	0.00511	CcSEcCtD
Clodronate—Hypercalcaemia—Epirubicin—sarcoma	0.0026	0.00508	CcSEcCtD
Clodronate—Abdominal pain upper—Mitoxantrone—sarcoma	0.00257	0.00502	CcSEcCtD
Clodronate—PTGS2—seminal vesicle—sarcoma	0.00252	0.00633	CbGeAlD
Clodronate—Pneumonia—Thiotepa—sarcoma	0.00252	0.00493	CcSEcCtD
Clodronate—Pneumonia—Dactinomycin—sarcoma	0.0025	0.0049	CcSEcCtD
Clodronate—SLC25A6—HIV Infection—NPM1—sarcoma	0.0025	0.036	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Mitoxantrone—sarcoma	0.00248	0.00485	CcSEcCtD
Clodronate—Renal failure—Thiotepa—sarcoma	0.00246	0.00482	CcSEcCtD
Clodronate—Hypercalcaemia—Doxorubicin—sarcoma	0.0024	0.0047	CcSEcCtD
Clodronate—PTGS2—hematopoietic system—sarcoma	0.0024	0.00602	CbGeAlD
Clodronate—Cardiac failure—Etoposide—sarcoma	0.00239	0.00468	CcSEcCtD
Clodronate—PTGS2—connective tissue—sarcoma	0.00231	0.00579	CbGeAlD
Clodronate—Pneumonia—Vincristine—sarcoma	0.00224	0.00437	CcSEcCtD
Clodronate—Urinary tract disorder—Thiotepa—sarcoma	0.00222	0.00435	CcSEcCtD
Clodronate—Pharyngitis—Dactinomycin—sarcoma	0.00222	0.00434	CcSEcCtD
Clodronate—Connective tissue disorder—Thiotepa—sarcoma	0.00221	0.00433	CcSEcCtD
Clodronate—Urethral disorder—Thiotepa—sarcoma	0.00221	0.00432	CcSEcCtD
Clodronate—Pneumonia—Mitoxantrone—sarcoma	0.00218	0.00426	CcSEcCtD
Clodronate—Renal failure—Mitoxantrone—sarcoma	0.00213	0.00416	CcSEcCtD
Clodronate—Neoplasm malignant—Epirubicin—sarcoma	0.00211	0.00413	CcSEcCtD
Clodronate—PTGS2—smooth muscle tissue—sarcoma	0.00211	0.0053	CbGeAlD
Clodronate—SLC25A5—HIV Infection—CXCR4—sarcoma	0.00211	0.0303	CbGpPWpGaD
Clodronate—PTGS2—skin of body—sarcoma	0.00209	0.00523	CbGeAlD
Clodronate—Extravasation—Epirubicin—sarcoma	0.00207	0.00405	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Etoposide—sarcoma	0.00206	0.00403	CcSEcCtD
Clodronate—Mediastinal disorder—Thiotepa—sarcoma	0.00203	0.00397	CcSEcCtD
Clodronate—Dysphagia—Etoposide—sarcoma	0.00202	0.00395	CcSEcCtD
Clodronate—Bronchospasm—Etoposide—sarcoma	0.00199	0.00389	CcSEcCtD
Clodronate—PTGS2—S1P1 pathway—PLCG1—sarcoma	0.00198	0.0285	CbGpPWpGaD
Clodronate—Hypocalcaemia—Epirubicin—sarcoma	0.00197	0.00386	CcSEcCtD
Clodronate—Urinary tract disorder—Vincristine—sarcoma	0.00197	0.00386	CcSEcCtD
Clodronate—Connective tissue disorder—Vincristine—sarcoma	0.00196	0.00384	CcSEcCtD
Clodronate—Oliguria—Epirubicin—sarcoma	0.00196	0.00383	CcSEcCtD
Clodronate—Urethral disorder—Vincristine—sarcoma	0.00196	0.00383	CcSEcCtD
Clodronate—Neoplasm malignant—Doxorubicin—sarcoma	0.00196	0.00383	CcSEcCtD
Clodronate—SLC25A4—HIV Infection—NPM1—sarcoma	0.00195	0.0281	CbGpPWpGaD
Clodronate—Pharyngitis—Mitoxantrone—sarcoma	0.00193	0.00377	CcSEcCtD
Clodronate—Extravasation—Doxorubicin—sarcoma	0.00191	0.00374	CcSEcCtD
Clodronate—Creatinine increased—Epirubicin—sarcoma	0.0019	0.00371	CcSEcCtD
Clodronate—Hypocalcaemia—Doxorubicin—sarcoma	0.00182	0.00357	CcSEcCtD
Clodronate—PTGS2—uterus—sarcoma	0.00181	0.00454	CbGeAlD
Clodronate—Oliguria—Doxorubicin—sarcoma	0.00181	0.00354	CcSEcCtD
Clodronate—Pneumonia—Etoposide—sarcoma	0.00181	0.00354	CcSEcCtD
Clodronate—Anaemia—Thiotepa—sarcoma	0.00181	0.00354	CcSEcCtD
Clodronate—Hepatocellular injury—Epirubicin—sarcoma	0.0018	0.00353	CcSEcCtD
Clodronate—Mediastinal disorder—Vincristine—sarcoma	0.0018	0.00352	CcSEcCtD
Clodronate—Anaemia—Dactinomycin—sarcoma	0.0018	0.00352	CcSEcCtD
Clodronate—Renal failure—Etoposide—sarcoma	0.00177	0.00346	CcSEcCtD
Clodronate—SLC25A6—HIV Infection—CXCR4—sarcoma	0.00176	0.0254	CbGpPWpGaD
Clodronate—Creatinine increased—Doxorubicin—sarcoma	0.00175	0.00343	CcSEcCtD
Clodronate—PTGS2—lymphoid tissue—sarcoma	0.00169	0.00424	CbGeAlD
Clodronate—Hepatocellular injury—Doxorubicin—sarcoma	0.00167	0.00327	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00166	0.00324	CcSEcCtD
Clodronate—Anaemia—Vincristine—sarcoma	0.00161	0.00314	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.0016	0.023	CbGpPWpGaD
Clodronate—Urinary tract disorder—Etoposide—sarcoma	0.0016	0.00312	CcSEcCtD
Clodronate—Infection—Thiotepa—sarcoma	0.00159	0.00311	CcSEcCtD
Clodronate—PTGS2—tendon—sarcoma	0.00159	0.00398	CbGeAlD
Clodronate—Urethral disorder—Etoposide—sarcoma	0.00158	0.0031	CcSEcCtD
Clodronate—Infection—Dactinomycin—sarcoma	0.00158	0.00308	CcSEcCtD
Clodronate—Anaemia—Mitoxantrone—sarcoma	0.00156	0.00306	CcSEcCtD
Clodronate—Skin disorder—Thiotepa—sarcoma	0.00155	0.00304	CcSEcCtD
Clodronate—PTGS2—bone marrow—sarcoma	0.00154	0.00386	CbGeAlD
Clodronate—Anorexia—Thiotepa—sarcoma	0.00152	0.00298	CcSEcCtD
Clodronate—Anorexia—Dactinomycin—sarcoma	0.00151	0.00296	CcSEcCtD
Clodronate—Hepatic function abnormal—Epirubicin—sarcoma	0.0015	0.00293	CcSEcCtD
Clodronate—Mediastinal disorder—Etoposide—sarcoma	0.00146	0.00285	CcSEcCtD
Clodronate—Renal failure acute—Epirubicin—sarcoma	0.00142	0.00278	CcSEcCtD
Clodronate—Infection—Vincristine—sarcoma	0.00141	0.00276	CcSEcCtD
Clodronate—Dyspepsia—Thiotepa—sarcoma	0.00141	0.00275	CcSEcCtD
Clodronate—PTGS2—S1P1 pathway—PDGFRB—sarcoma	0.0014	0.0202	CbGpPWpGaD
Clodronate—Decreased appetite—Thiotepa—sarcoma	0.00139	0.00272	CcSEcCtD
Clodronate—Hepatic function abnormal—Doxorubicin—sarcoma	0.00139	0.00271	CcSEcCtD
Clodronate—Gastrointestinal disorder—Thiotepa—sarcoma	0.00138	0.0027	CcSEcCtD
Clodronate—Decreased appetite—Dactinomycin—sarcoma	0.00138	0.0027	CcSEcCtD
Clodronate—SLC25A4—HIV Infection—CXCR4—sarcoma	0.00138	0.0198	CbGpPWpGaD
Clodronate—Renal impairment—Epirubicin—sarcoma	0.00138	0.00269	CcSEcCtD
Clodronate—Infection—Mitoxantrone—sarcoma	0.00137	0.00268	CcSEcCtD
Clodronate—Anorexia—Vincristine—sarcoma	0.00135	0.00264	CcSEcCtD
Clodronate—Cardiac failure—Epirubicin—sarcoma	0.00134	0.00263	CcSEcCtD
Clodronate—Skin disorder—Mitoxantrone—sarcoma	0.00134	0.00262	CcSEcCtD
Clodronate—Anorexia—Mitoxantrone—sarcoma	0.00132	0.00258	CcSEcCtD
Clodronate—Renal failure acute—Doxorubicin—sarcoma	0.00131	0.00257	CcSEcCtD
Clodronate—Anaemia—Etoposide—sarcoma	0.0013	0.00254	CcSEcCtD
Clodronate—Renal impairment—Doxorubicin—sarcoma	0.00127	0.00249	CcSEcCtD
Clodronate—Urticaria—Thiotepa—sarcoma	0.00127	0.00249	CcSEcCtD
Clodronate—Abdominal pain—Thiotepa—sarcoma	0.00126	0.00247	CcSEcCtD
Clodronate—Abdominal pain—Dactinomycin—sarcoma	0.00125	0.00245	CcSEcCtD
Clodronate—PTGS2—liver—sarcoma	0.00124	0.00312	CbGeAlD
Clodronate—Cardiac failure—Doxorubicin—sarcoma	0.00124	0.00243	CcSEcCtD
Clodronate—Decreased appetite—Vincristine—sarcoma	0.00123	0.00241	CcSEcCtD
Clodronate—Dyspnoea—Mitoxantrone—sarcoma	0.00123	0.00241	CcSEcCtD
Clodronate—Blood creatinine increased—Epirubicin—sarcoma	0.00123	0.0024	CcSEcCtD
Clodronate—Gastrointestinal disorder—Vincristine—sarcoma	0.00122	0.00239	CcSEcCtD
Clodronate—Dehydration—Epirubicin—sarcoma	0.00122	0.00238	CcSEcCtD
Clodronate—Dyspepsia—Mitoxantrone—sarcoma	0.00122	0.00238	CcSEcCtD
Clodronate—Decreased appetite—Mitoxantrone—sarcoma	0.0012	0.00235	CcSEcCtD
Clodronate—Abdominal pain upper—Epirubicin—sarcoma	0.0012	0.00234	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00119	0.00233	CcSEcCtD
Clodronate—PTGS2—S1P1 pathway—KDR—sarcoma	0.00116	0.0168	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Epirubicin—sarcoma	0.00116	0.00226	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.00115	0.0166	CbGpPWpGaD
Clodronate—Infection—Etoposide—sarcoma	0.00114	0.00223	CcSEcCtD
Clodronate—Blood creatinine increased—Doxorubicin—sarcoma	0.00114	0.00222	CcSEcCtD
Clodronate—Dysphagia—Epirubicin—sarcoma	0.00113	0.00222	CcSEcCtD
Clodronate—Pruritus—Thiotepa—sarcoma	0.00113	0.00221	CcSEcCtD
Clodronate—Dehydration—Doxorubicin—sarcoma	0.00113	0.00221	CcSEcCtD
Clodronate—Abdominal pain—Vincristine—sarcoma	0.00112	0.00219	CcSEcCtD
Clodronate—Skin disorder—Etoposide—sarcoma	0.00112	0.00218	CcSEcCtD
Clodronate—Abdominal pain upper—Doxorubicin—sarcoma	0.00111	0.00217	CcSEcCtD
Clodronate—Urticaria—Mitoxantrone—sarcoma	0.0011	0.00215	CcSEcCtD
Clodronate—Anorexia—Etoposide—sarcoma	0.00109	0.00214	CcSEcCtD
Clodronate—Diarrhoea—Thiotepa—sarcoma	0.00109	0.00214	CcSEcCtD
Clodronate—Abdominal pain—Mitoxantrone—sarcoma	0.00109	0.00214	CcSEcCtD
Clodronate—Diarrhoea—Dactinomycin—sarcoma	0.00109	0.00212	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.00107	0.00209	CcSEcCtD
Clodronate—Dysphagia—Doxorubicin—sarcoma	0.00105	0.00205	CcSEcCtD
Clodronate—Dyspnoea—Etoposide—sarcoma	0.00102	0.002	CcSEcCtD
Clodronate—Vomiting—Thiotepa—sarcoma	0.00102	0.00199	CcSEcCtD
Clodronate—Pneumonia—Epirubicin—sarcoma	0.00102	0.00199	CcSEcCtD
Clodronate—Vomiting—Dactinomycin—sarcoma	0.00101	0.00197	CcSEcCtD
Clodronate—Rash—Thiotepa—sarcoma	0.00101	0.00197	CcSEcCtD
Clodronate—Dermatitis—Thiotepa—sarcoma	0.00101	0.00197	CcSEcCtD
Clodronate—Rash—Dactinomycin—sarcoma	0.001	0.00196	CcSEcCtD
Clodronate—Decreased appetite—Etoposide—sarcoma	0.000998	0.00195	CcSEcCtD
Clodronate—Renal failure—Epirubicin—sarcoma	0.000992	0.00194	CcSEcCtD
Clodronate—Gastrointestinal disorder—Etoposide—sarcoma	0.000991	0.00194	CcSEcCtD
Clodronate—Diarrhoea—Vincristine—sarcoma	0.00097	0.0019	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000957	0.0138	CbGpPWpGaD
Clodronate—PTGS2—lymph node—sarcoma	0.000953	0.00239	CbGeAlD
Clodronate—Nausea—Thiotepa—sarcoma	0.00095	0.00186	CcSEcCtD
Clodronate—Diarrhoea—Mitoxantrone—sarcoma	0.000945	0.00185	CcSEcCtD
Clodronate—Nausea—Dactinomycin—sarcoma	0.000943	0.00184	CcSEcCtD
Clodronate—Pneumonia—Doxorubicin—sarcoma	0.000939	0.00184	CcSEcCtD
Clodronate—Renal failure—Doxorubicin—sarcoma	0.000918	0.0018	CcSEcCtD
Clodronate—Urticaria—Etoposide—sarcoma	0.000912	0.00179	CcSEcCtD
Clodronate—Abdominal pain—Etoposide—sarcoma	0.000908	0.00178	CcSEcCtD
Clodronate—Vomiting—Vincristine—sarcoma	0.000901	0.00176	CcSEcCtD
Clodronate—Pharyngitis—Epirubicin—sarcoma	0.000899	0.00176	CcSEcCtD
Clodronate—Urinary tract disorder—Epirubicin—sarcoma	0.000895	0.00175	CcSEcCtD
Clodronate—Rash—Vincristine—sarcoma	0.000894	0.00175	CcSEcCtD
Clodronate—Dermatitis—Vincristine—sarcoma	0.000893	0.00175	CcSEcCtD
Clodronate—Connective tissue disorder—Epirubicin—sarcoma	0.00089	0.00174	CcSEcCtD
Clodronate—Urethral disorder—Epirubicin—sarcoma	0.000888	0.00174	CcSEcCtD
Clodronate—Vomiting—Mitoxantrone—sarcoma	0.000878	0.00172	CcSEcCtD
Clodronate—Rash—Mitoxantrone—sarcoma	0.000871	0.0017	CcSEcCtD
Clodronate—Dermatitis—Mitoxantrone—sarcoma	0.00087	0.0017	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—CD34—sarcoma	0.000853	0.0123	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—MYOD1—sarcoma	0.000853	0.0123	CbGpPWpGaD
Clodronate—Nausea—Vincristine—sarcoma	0.000842	0.00165	CcSEcCtD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	0.000842	0.0121	CbGpPWpGaD
Clodronate—Pharyngitis—Doxorubicin—sarcoma	0.000832	0.00163	CcSEcCtD
Clodronate—Urinary tract disorder—Doxorubicin—sarcoma	0.000828	0.00162	CcSEcCtD
Clodronate—Connective tissue disorder—Doxorubicin—sarcoma	0.000824	0.00161	CcSEcCtD
Clodronate—Urethral disorder—Doxorubicin—sarcoma	0.000822	0.00161	CcSEcCtD
Clodronate—Nausea—Mitoxantrone—sarcoma	0.00082	0.0016	CcSEcCtD
Clodronate—Mediastinal disorder—Epirubicin—sarcoma	0.000817	0.0016	CcSEcCtD
Clodronate—Pruritus—Etoposide—sarcoma	0.000813	0.00159	CcSEcCtD
Clodronate—SLC25A5—Disease—TLE1—sarcoma	0.00081	0.0117	CbGpPWpGaD
Clodronate—Diarrhoea—Etoposide—sarcoma	0.000786	0.00154	CcSEcCtD
Clodronate—Mediastinal disorder—Doxorubicin—sarcoma	0.000756	0.00148	CcSEcCtD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—sarcoma	0.000735	0.0106	CbGpPWpGaD
Clodronate—SLC25A5—Disease—NPM1—sarcoma	0.000731	0.0105	CbGpPWpGaD
Clodronate—Vomiting—Etoposide—sarcoma	0.00073	0.00143	CcSEcCtD
Clodronate—Anaemia—Epirubicin—sarcoma	0.000729	0.00143	CcSEcCtD
Clodronate—Rash—Etoposide—sarcoma	0.000724	0.00142	CcSEcCtD
Clodronate—Dermatitis—Etoposide—sarcoma	0.000723	0.00142	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—JUN—sarcoma	0.000688	0.00992	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000683	0.00984	CbGpPWpGaD
Clodronate—Nausea—Etoposide—sarcoma	0.000682	0.00133	CcSEcCtD
Clodronate—PTGS2—Selenium Micronutrient Network—HBA1—sarcoma	0.000681	0.00981	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TLE1—sarcoma	0.000679	0.00978	CbGpPWpGaD
Clodronate—Anaemia—Doxorubicin—sarcoma	0.000675	0.00132	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000667	0.0013	CcSEcCtD
Clodronate—PTGS2—S1P1 pathway—VEGFA—sarcoma	0.000641	0.00923	CbGpPWpGaD
Clodronate—Infection—Epirubicin—sarcoma	0.00064	0.00125	CcSEcCtD
Clodronate—SLC25A5—Disease—ENO2—sarcoma	0.000633	0.00912	CbGpPWpGaD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.000626	0.00901	CbGpPWpGaD
Clodronate—Skin disorder—Epirubicin—sarcoma	0.000625	0.00122	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000617	0.00121	CcSEcCtD
Clodronate—Anorexia—Epirubicin—sarcoma	0.000614	0.0012	CcSEcCtD
Clodronate—SLC25A6—Disease—NPM1—sarcoma	0.000612	0.00882	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.000601	0.00866	CbGpPWpGaD
Clodronate—Infection—Doxorubicin—sarcoma	0.000592	0.00116	CcSEcCtD
Clodronate—Skin disorder—Doxorubicin—sarcoma	0.000579	0.00113	CcSEcCtD
Clodronate—Dyspnoea—Epirubicin—sarcoma	0.000574	0.00112	CcSEcCtD
Clodronate—Anorexia—Doxorubicin—sarcoma	0.000568	0.00111	CcSEcCtD
Clodronate—Dyspepsia—Epirubicin—sarcoma	0.000567	0.00111	CcSEcCtD
Clodronate—Decreased appetite—Epirubicin—sarcoma	0.00056	0.0011	CcSEcCtD
Clodronate—Gastrointestinal disorder—Epirubicin—sarcoma	0.000556	0.00109	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—sarcoma	0.000538	0.00774	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PLCG1—sarcoma	0.000537	0.00774	CbGpPWpGaD
Clodronate—Dyspnoea—Doxorubicin—sarcoma	0.000531	0.00104	CcSEcCtD
Clodronate—SLC25A6—Disease—ENO2—sarcoma	0.00053	0.00764	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—ENO2—sarcoma	0.00053	0.00763	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TLE1—sarcoma	0.00053	0.00763	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—HBA1—sarcoma	0.000527	0.00759	CbGpPWpGaD
Clodronate—Dyspepsia—Doxorubicin—sarcoma	0.000524	0.00103	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—sarcoma	0.000523	0.00753	CbGpPWpGaD
Clodronate—Decreased appetite—Doxorubicin—sarcoma	0.000518	0.00101	CcSEcCtD
Clodronate—SLC25A5—Disease—CXCR4—sarcoma	0.000516	0.00743	CbGpPWpGaD
Clodronate—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000514	0.00101	CcSEcCtD
Clodronate—Urticaria—Epirubicin—sarcoma	0.000511	0.001	CcSEcCtD
Clodronate—Abdominal pain—Epirubicin—sarcoma	0.000509	0.000996	CcSEcCtD
Clodronate—SLC25A4—Disease—NPM1—sarcoma	0.000478	0.00688	CbGpPWpGaD
Clodronate—Urticaria—Doxorubicin—sarcoma	0.000473	0.000926	CcSEcCtD
Clodronate—Abdominal pain—Doxorubicin—sarcoma	0.000471	0.000921	CcSEcCtD
Clodronate—Pruritus—Epirubicin—sarcoma	0.000455	0.000891	CcSEcCtD
Clodronate—SLC25A6—Disease—PLCG1—sarcoma	0.00045	0.00648	CbGpPWpGaD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.00045	0.00648	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PLCG1—sarcoma	0.00045	0.00648	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—ENO2—sarcoma	0.000444	0.0064	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—HBA1—sarcoma	0.000441	0.00636	CbGpPWpGaD
Clodronate—Diarrhoea—Epirubicin—sarcoma	0.00044	0.000862	CcSEcCtD
Clodronate—SLC25A6—Disease—CXCR4—sarcoma	0.000432	0.00623	CbGpPWpGaD
Clodronate—Pruritus—Doxorubicin—sarcoma	0.000421	0.000825	CcSEcCtD
Clodronate—SLC25A4—Disease—ENO2—sarcoma	0.000414	0.00596	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000411	0.00592	CbGpPWpGaD
Clodronate—Vomiting—Epirubicin—sarcoma	0.000409	0.000801	CcSEcCtD
Clodronate—Diarrhoea—Doxorubicin—sarcoma	0.000408	0.000797	CcSEcCtD
Clodronate—Rash—Epirubicin—sarcoma	0.000406	0.000794	CcSEcCtD
Clodronate—Dermatitis—Epirubicin—sarcoma	0.000406	0.000794	CcSEcCtD
Clodronate—Nausea—Epirubicin—sarcoma	0.000382	0.000748	CcSEcCtD
Clodronate—SLC25A5—Disease—FOXO1—sarcoma	0.000381	0.00549	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PDGFRB—sarcoma	0.00038	0.00548	CbGpPWpGaD
Clodronate—Vomiting—Doxorubicin—sarcoma	0.000379	0.000741	CcSEcCtD
Clodronate—SLC25A6—Metabolism—PLCG1—sarcoma	0.000377	0.00543	CbGpPWpGaD
Clodronate—Rash—Doxorubicin—sarcoma	0.000376	0.000735	CcSEcCtD
Clodronate—Dermatitis—Doxorubicin—sarcoma	0.000375	0.000734	CcSEcCtD
Clodronate—SLC25A5—Disease—PDGFRA—sarcoma	0.000374	0.00539	CbGpPWpGaD
Clodronate—Nausea—Doxorubicin—sarcoma	0.000354	0.000692	CcSEcCtD
Clodronate—SLC25A4—Disease—PLCG1—sarcoma	0.000351	0.00506	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—MMP2—sarcoma	0.00035	0.00505	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.000348	0.00501	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—ENO2—sarcoma	0.000347	0.00499	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—HBA1—sarcoma	0.000345	0.00496	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.000338	0.00487	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CXCR4—sarcoma	0.000338	0.00486	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—KIT—sarcoma	0.000326	0.0047	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000324	0.00467	CbGpPWpGaD
Clodronate—SLC25A6—Disease—FOXO1—sarcoma	0.000319	0.0046	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PDGFRB—sarcoma	0.000319	0.00459	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000316	0.00455	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PDGFRA—sarcoma	0.000314	0.00452	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000312	0.00449	CbGpPWpGaD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.000297	0.00428	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PLCG1—sarcoma	0.000294	0.00424	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000291	0.00419	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KIT—sarcoma	0.00029	0.00418	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000284	0.00409	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CREB1—sarcoma	0.000276	0.00398	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—MMP2—sarcoma	0.000273	0.00394	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—CTNNB1—sarcoma	0.000269	0.00387	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000269	0.00387	CbGpPWpGaD
Clodronate—SLC25A4—Disease—FOXO1—sarcoma	0.000249	0.00359	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PDGFRB—sarcoma	0.000249	0.00358	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PDGFRA—sarcoma	0.000245	0.00353	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KIT—sarcoma	0.000243	0.0035	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CREB1—sarcoma	0.000232	0.00334	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MDM2—sarcoma	0.000229	0.00329	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000228	0.00329	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CCND1—sarcoma	0.000224	0.00322	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000218	0.00314	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—CTNNB1—sarcoma	0.00021	0.00302	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CTNNB1—sarcoma	0.000197	0.00284	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—NRAS—sarcoma	0.000193	0.00278	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MDM2—sarcoma	0.000192	0.00276	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KIT—sarcoma	0.00019	0.00274	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CREB1—sarcoma	0.000181	0.0026	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—MYC—sarcoma	0.00018	0.00259	CbGpPWpGaD
Clodronate—SLC25A5—Disease—SRC—sarcoma	0.000178	0.00257	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL2—sarcoma	0.000175	0.00252	CbGpPWpGaD
Clodronate—SLC25A5—Disease—NRAS—sarcoma	0.000172	0.00247	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCND1—sarcoma	0.000171	0.00246	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—KRAS—sarcoma	0.000166	0.00239	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CTNNB1—sarcoma	0.000165	0.00238	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000161	0.00232	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MYC—sarcoma	0.00016	0.0023	CbGpPWpGaD
Clodronate—SLC25A5—Disease—EGFR—sarcoma	0.000156	0.00225	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MDM2—sarcoma	0.00015	0.00215	CbGpPWpGaD
Clodronate—SLC25A6—Disease—SRC—sarcoma	0.000149	0.00215	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KRAS—sarcoma	0.000148	0.00213	CbGpPWpGaD
Clodronate—SLC25A6—Disease—NRAS—sarcoma	0.000144	0.00207	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	0.000141	0.00203	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MYC—sarcoma	0.000137	0.00197	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MYC—sarcoma	0.000134	0.00193	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—EGFR—sarcoma	0.000134	0.00193	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000133	0.00192	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EGFR—sarcoma	0.000131	0.00189	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CTNNB1—sarcoma	0.000129	0.00186	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HRAS—sarcoma	0.000125	0.00181	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KRAS—sarcoma	0.000124	0.00178	CbGpPWpGaD
Clodronate—SLC25A4—Disease—SRC—sarcoma	0.000117	0.00168	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000116	0.00167	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000116	0.00167	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000115	0.00165	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—sarcoma	0.000112	0.00162	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NRAS—sarcoma	0.000112	0.00162	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HRAS—sarcoma	0.000105	0.00151	CbGpPWpGaD
Clodronate—PTGS2—Disease—TLE1—sarcoma	0.000105	0.00151	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MYC—sarcoma	0.000105	0.00151	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000104	0.0015	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EGFR—sarcoma	0.000102	0.00147	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000101	0.00146	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KRAS—sarcoma	9.66e-05	0.00139	CbGpPWpGaD
Clodronate—PTGS2—Disease—NPM1—sarcoma	9.45e-05	0.00136	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	9.3e-05	0.00134	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	9.1e-05	0.00131	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	8.6e-05	0.00124	CbGpPWpGaD
Clodronate—SLC25A4—Disease—HRAS—sarcoma	8.21e-05	0.00118	CbGpPWpGaD
Clodronate—PTGS2—Disease—ENO2—sarcoma	8.19e-05	0.00118	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	7.64e-05	0.0011	CbGpPWpGaD
Clodronate—PTGS2—Disease—PLCG1—sarcoma	6.95e-05	0.001	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ENO2—sarcoma	6.86e-05	0.000987	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HBA1—sarcoma	6.81e-05	0.000981	CbGpPWpGaD
Clodronate—PTGS2—Disease—CXCR4—sarcoma	6.67e-05	0.000961	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PLCG1—sarcoma	5.82e-05	0.000838	CbGpPWpGaD
Clodronate—PTGS2—Disease—FOXO1—sarcoma	4.93e-05	0.00071	CbGpPWpGaD
Clodronate—PTGS2—Disease—PDGFRB—sarcoma	4.92e-05	0.000709	CbGpPWpGaD
Clodronate—PTGS2—Disease—PDGFRA—sarcoma	4.84e-05	0.000698	CbGpPWpGaD
Clodronate—PTGS2—Disease—KIT—sarcoma	3.76e-05	0.000541	CbGpPWpGaD
Clodronate—PTGS2—Disease—CREB1—sarcoma	3.57e-05	0.000515	CbGpPWpGaD
Clodronate—PTGS2—Disease—MDM2—sarcoma	2.96e-05	0.000426	CbGpPWpGaD
Clodronate—PTGS2—Disease—CTNNB1—sarcoma	2.55e-05	0.000367	CbGpPWpGaD
Clodronate—PTGS2—Disease—SRC—sarcoma	2.31e-05	0.000332	CbGpPWpGaD
Clodronate—PTGS2—Disease—NRAS—sarcoma	2.22e-05	0.00032	CbGpPWpGaD
Clodronate—PTGS2—Disease—MYC—sarcoma	2.07e-05	0.000298	CbGpPWpGaD
Clodronate—PTGS2—Disease—EGFR—sarcoma	2.02e-05	0.000291	CbGpPWpGaD
Clodronate—PTGS2—Disease—KRAS—sarcoma	1.91e-05	0.000275	CbGpPWpGaD
Clodronate—PTGS2—Disease—HRAS—sarcoma	1.62e-05	0.000234	CbGpPWpGaD
